| Literature DB >> 20810804 |
Joseph V Woodring1, Bernhards Ogutu, David Schnabel, John N Waitumbi, Cara H Olsen, Douglas S Walsh, D Gray Heppner, Mark E Polhemus.
Abstract
From April 2005 to April 2006, a phase 2 malaria vaccine trial in Kenya enrolled 400 children aged 12-47 months. Each received mixed supervised and unsupervised artemether-lumefantrine for uncomplicated malaria, using a standard six-dose regimen, by weight. Children were followed for detection of parasitemia and clinical malaria. A median of two negative malaria blood films occurred during every recurrent parasitemia (RP) episode, suggesting reinfection over late recrudescence. Median time to RP after starting artemether-lumefantrine was 37 days (36-38). Of 2,020 evaluable artemether-lumefantrine treatments, there were no RPs in 99% by day 14, 71% by day 28, and 41% by day 42. By World Health Organization standards, 71% of treatment courses had adequate responses. Although recrudescence in some cannot be ruled out, our cohort had a shorter median time to RP compared with other artemether-lumefantrine treatment studies. This underscores patient counseling on completing all treatment doses for optimal protection from RP.Entities:
Mesh：
Substances：
Year: 2010 PMID： 20810804 PMCID： PMC2929035 DOI： 10.4269/ajtmh.2010.09-0403
Source DB: PubMed Journal: Am J Trop Med Hyg ISSN： 0002-9637 Impact factor: 2.345